Highlights BetterLife Pharma Inc.

Equities

BETRF

CA08772P2026

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:34:44 2025-07-08 pm EDT			5-day change	1st Jan Change
0.0641 ^USD	+5.25%		+1.10%	-10.97%

Jun. 27	BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2025	CI
May. 29	BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2025	CI

Highlights

BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2025	Jun. 27	CI
BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2025	May. 29	CI
Betterlife Pharma Provides Scientific Update On Neuroplastogenic Activity Of BETR-001	May. 28	RE
Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001	May. 28	CI
BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders	May. 14	CI
BetterLife Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2024	Dec. 27	CI
BetterLife Pharma Inc. Obtains Cardiac Safety Data for BETR-001	Nov. 25	CI
BetterLife Pharma Inc. Obtains Favourable Genotoxicity Data for Oral BETR-001	24-10-23	CI
BetterLife Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2024	24-09-25	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024	24-06-27	CI
BetterLife Pharma Raises $530,000 in Private Placement	24-06-14	MT
BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2024	24-05-29	CI
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001	24-05-14	CI
BetterLife Pharma Advances IND-enabling Studies For BETR-001	24-05-01	MT
BetterLife Pharma Inc. Advances BETR-001 IND-Enabling Studies	24-05-01	CI
BetterLife Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	23-12-29	CI
Us Patent and Trademark Office Publishes Betterlife?S Comprehensive Patent for Betr-001 and Other Lsd Derivatives	23-11-30	CI
BetterLife Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-27	CI
BetterLife Pharma Inc. Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001	23-09-12	CI
BetterLife Pharma Inc. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-28	CI
BetterLife Pharma Inc. Fast Tracking Its US Patent for BETR-001 and Other LSD Derivatives	23-06-27	CI
BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling Studies	23-06-08	CI
BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2023	23-05-31	CI
BetterLife Pharma Inc. to Present BETR-001 Preclinical Data At the 2023 Annual Meeting of the Society of Biological Psychiatry in San Diego, California	23-04-25	CI
BetterLife Pharma Inc. Publishes Promising Results from Study Titled "A Non-Hallucinogenic LSD Analog with Therapeutic Potential for Mood Disorders	23-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BetterLife Pharma Inc.

Equities

BETRF

CA08772P2026

Biotechnology & Medical Research

Highlights

Filters